Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: A systematic review of the literature

Cancer

Volumn 110, Issue 7, 2007, Pages 1417-1428

  Nguyen, Paul L ^a   D'Amico, Anthony V ^a   Lee, Andrew K ^b   Suh, W Warren ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Brachytherapy; Cryosurgery; Local neoplasm recurrence; Prostate cancer; Prostate specific antigen; Prostatectomy; Salvage therapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLADDER NECK STENOSIS; BRACHYTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CRYOSURGERY; EXTERNAL BEAM RADIOTHERAPY; FISTULA; GLEASON SCORE; HUMAN; MICROMETASTASIS; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RECTUM INJURY; REVIEW; SALVAGE THERAPY; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TREATMENT FAILURE; URINE INCONTINENCE; UROGENITAL TRACT DISEASE;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CRYOSURGERY; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PATIENT SELECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; URINARY FISTULA; URINARY INCONTINENCE;

EID: 34648825019     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22941     Document Type: Review

References (86)

1. Blasko JC, Grimm PD, Sylvester JE, et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys. 2000;46:839-850.
2. Pollack A, Hanlon AL, Horwitz EM, et al. Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol. 2004;171:1132-1136.
3. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: a multiinstitutional pooled analysis. JAMA. 1999;281:1598-1604.
4. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327-333.
5. Bianco FJ Jr, Scardino PT, Stephenson AJ, et al. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:448-453.
6. Chin JL, Pautler SE, Mouraviev V, et al. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol. 2001;165:1937-1941; discussion 1941-1932.
7. Grado GL, Collins JM, Kriegshauser JS, et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology. 1999;53:2-10.
8. Izawa JI, Madsen LT, Scott SM, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002;20:2664-2671.
9. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. J Clin Oncol. 1997;15:230-238.
10. Ward JF, Sebo TJ, Blute ML, et al. Salvage surgery for radio-recurrent prostate cancer: contemporary outcomes. J Urol. 2005;173:1156-1160.
11. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
12. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997;44:213-221.
13. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
14. Bostwick DG, Egbert BM, Fajardo LF. Radiation injury of the normal and neoplastic prostate. Am J Surg Pathol. 1982;6:541-551.
15. Amin MB, Grignon D, Humphrey PA, et al. Gleason Grading of Prostate Cancer: A Contemporary Approach. Philadelphia: Lippincott Williams & Wilkins; 2003.
16. Humphrey PA. Prostate Pathology. 3rd ed. Chicago, Ill: American Society of Clinical Pathology; 2003.
17. Crook J, Malone S, Perry G, et al. Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys. 2000;48:355-367.
18. Scardino PT. The prognostic significance of biopsies after radiotherapy for prostatic cancer. Semin Urol. 1983;1:243-252.
19. Crook JM, Perry GA, Robertson S, et al. Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients. Urology. 1995;45:624-631; discussion 631-622.
20. D'Amico AV, Moul J, Carroll PR, et al. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003;21:2163-2172.
21. D'Amico AV, Whittington R, Malkowicz SB, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168-172.
22. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003;21:4568-4571.
23. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer. 1993;72:1709-1725.
24. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.
25. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440-447.
26. Berger AP, Deibl M, Strasak A, et al. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population. Urology. 2006;68:1067-1071.
27. Martinez CA, Dall'Oglio M, Nesrallah L, et al. Predictive value of PSA velocity over early clinical and pathological parameters in patients with localized prostate cancer who undergo radical retropubic prostatectomy. Int Braz J Urol. 2004;30:12-17.
28. Patel DA, Presti JC Jr, McNeal JE, et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005;23:6157-6162.
29. Freedland SJ, Humphreys EB, Mangold LA, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005;294:433-439.
30. Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005;23:826-831.
31. D'Amico AV, Moul J, Carroll PR, et al. Surrogate end point for prostate cancer specific mortality in patients with non-metastatic hormone refractory prostate cancer. J Urol. 2005;173:1572-1576.
32. D'Amico AV, Moul JW, Carroll PR, et al. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
33. de la Taille A, Hayek O, Benson MC, et al. Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology. 2000;55:79-84.
34. Amling CL, Lerner SE, Martin SK, et al. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer. J Urol. 1999;161:857-862; discussion 862-853.
35. Rogers E, Ohori M, Kassabian VS, et al. Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol. 1995;153:104-110.
36. Dall'Oglio MF, Barreto F, Paranhos M, et al. Salvage radical prostatectomy: an alternative treatment for local recurrence of radioresistant cancer. Int Braz J Urol. 2006;32:550-556.
37. Darras J, Joniau S, Van Poppel H. Salvage radical prostatectomy for radiorecurrent prostate cancer: indications and results. Eur J Surg Oncol. 2006;32:964-969.
38. Garzotto M, Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year follow-up. J Urol. 1998;159:950-954; discussion 954-955.
39. Gheiler EL, Tefilli MV, Tiguert R, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998;51:789-795.
40. Link P, Freiha FS. Radical prostatectomy after definitive radiation therapy for prostate cancer. Urology. 1991;37:189-192.
41. Moul JW, Paulson DF. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer. 1991;68:1265-1271.
42. Pisters LL, English SF, Scott SM, et al. Salvage prostatectomy with continent catheterizable urinary reconstruction: a novel approach to recurrent prostate cancer after radiation therapy. J Urol. 2000;163:1771-1774.
43. Sanderson KM, Penson DF, Cai J, et al. Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol. 2006;176:2025-2031; discussion 2031-2022.
44. Stein A, Smith RB, deKernion JB. Salvage radical prostatectomy after failure of curative radiotherapy for adenocarcinoma of prostate. Urology. 1992;40:197-200.
45. Vaidya A, Soloway MS. Salvage radical prostatectomy for radiorecurrent prostate cancer: morbidity revisited. J Urol. 2000;164:1998-2001.
46. Vallancien G, Gupta R, Cathelineau X, et al. Initial results of salvage laparoscopic radical prostatectomy after radiation failure. J Urol. 2003;170:1838-1840.
47. van der Poel HG, Beetsma DB, van Boven H, et al. Perineal salvage prostatectomy for radiation resistant prostate cancer. Eur Urol. 2007;51:1565-1571; discussion 1572.
48. Cheng L, Sebo TJ, Slezak J, et al. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer. 1998;83:2164-2171.
49. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170:791-794.
50. Schulman CC, Debruyne FM, Forster G, et al. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38:706-713.
51. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167:112-116.
52. Gunderson LL, Tepper JE. Clinical Radiation Oncology. 2nd ed. Philadelphia: Elsevier-Churchill Livingstone; 2007.
53. Onik GM, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72:1291-1299.
54. Cohen JK, Miller RJ. Thermal protection of urethra during cryosurgery of prostate. Cryobiology. 1994;31:313-316.
55. Cohen JK, Miller RJ, Shuman BA. Urethral warming catheter for use during cryoablation of the prostate. Urology. 1995;45:861-864.
56. Bahn DK, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer. 2003;2:111-114.
57. Bales GT, Williams MJ, Sinner M, et al. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology. 1995;46:676-680.
58. Donnelly BJ, Saliken JC, Ernst DS, et al. Role of transrectal ultrasound guided salvage cryosurgery for recurrent prostate carcinoma after radiotherapy. Prostate Cancer Prostatic Dis. 2005;8:235-242.
59. Ghafar MA, Johnson CW, de la Taille A, et al. Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol. 2001;166:1333-1337; discussion 1337-1338.
60. Han KR, Cohen JK, Miller RJ, et al. Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003;170:1126-1130.
61. Miller RJ Jr, Cohen JK, Shuman B, et al. Percutaneous, transperineal cryosurgery of the prostate as salvage therapy for post radiation recurrence of adenocarcinoma. Cancer. 1996;77:1510-1514.
62. Spiess PE, Lee AK, Leibovici D, et al. Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer. 2006;107:275-280.
63. Izawa JI, Morganstern N, Chan DM, et al. Incomplete glandular ablation after salvage cryotherapy for recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2003;56:468-472.
64. Izawa JI, Ajam K, McGuire E, et al. Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer. J Urol. 2000;164:1978-1981.
65. Long JP, Fallick ML, LaRock DR, et al. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. J Urol. 1998;159:477-484.
66. Perrotte P, Litwin MS, McGuire EJ, et al. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol. 1999;162:398-402.
67. Pisters LL, von Eschenbach AC, Scott SM, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157:921-925.
68. Pasteau O. Traitment du cancer de la prostate par le radium. Rev Malad Nutr. 1911:363-367.
69. Koutrouvelis P, Hendricks F, Lailas N, et al. Salvage reimplantation in patient with local recurrent prostate carcinoma after brachytherapy with three dimensional computed tomography-guided permanent pararectal implant. Technol Cancer Res Treat. 2003;2:339-344.
70. Lee B, Shinohara K, Weinberg V, et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys. 2007;67:1106-1112.
71. Lo K, Stock RG, Stone NN. Salvage prostate brachytherapy following radiotherapy failure. Int J Radiat Oncol Biol Phys. 2005;63:S290-S291.
72. Nguyen PL, Chen MH, D'Amico AV et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007;110:1485-1492.
73. Wong WW, Buskirk SJ, Schild SE, et al. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol. 2006;176:2020-2024.
74. Beyer DC. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology. 1999;54:880-883.
75. Wallner KE, Nori D, Morse MJ, et al. 125iodine reimplantation for locally progressive prostatic carcinoma. J Urol. 1990;144:704-706.
76. Loening SA, Turner JW. Use of percutaneous transperineal 198Au seeds to treat recurrent prostate adenocarcinoma after failure of definitive radiotherapy. Prostate. 1993;23:283-290.
77. Dattoli M, Cash J, Ross R, et al. Neoadjuvant hormone therapy and palladium-103 brachytherapy as salvage for locally recurrent prostate cancer. Proc Am Soc Clin Oncol. 1997;16:1118. Abstract.
78. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys. 1997;37:1035-1041.
79. Vicini FA, Kestin LL, Martinez AA. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1999;45:553-561.
80. Stephenson AJ, Scardino PT, Bianco FJ, et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol. 2004;172:2239-2243.
81. Gelet A, Chapelon JY, Poissonnier L, et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology. 2004;63:625-629.
82. Kadoch C, D'Amico AV, Matthews RH. When prostate brachytherapy fails: a case report and discussion. Oncologist. 2005;10:799-805.
83. Master VA, Shinohara K, Carroll PR. Ferromagnetic thermal ablation of locally recurrent prostate cancer: prostate specific antigen results and immediate/intermediate morbidities. J Urol. 2004;172:2197-2202.
84. McCann C, Kumaradas JC, Gertner MR, et al. Feasibility of salvage interstitial microwave thermal therapy for prostate carcinoma following failed brachytherapy: studies in a tissue equivalent phantom. Phys Med Biol. 2003;48:1041-1052.
85. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233-1239.
86. Pollack A, Zagars GK, Smith LG, et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000;18:3904-3911.